Merck Sharp & Dohme (MSD)

Cyprumed and MSD Enter Licensing Agreement for Oral Peptide Therapeutics

MSD receives a non-exclusive license for Cyprumed's drug delivery technology for developing oral peptide therapeutics.

Merck & Co. Breaks Ground on $1 Billion Biologics Center in US

Merck Wilmington Biotech will serve as a launch and commercial production facility and the future US home for Keytruda.

MSD Licenses Cardiovascular Drug from Hengrui Pharma

MSD (Merck & Co.) and Hengrui Pharma recently announced that they have entered into an exclusive license agreement for HRS-5346, an investigational oral small molecule Lipoprotein(a) inhibitor.

MSD to Buy B-Cell Depletion Therapy from Curon

Major US drugmaker MSD is to pay up to $1.3 billion to acquire CN201, a novel investigational clinical-stage bispecific antibody for the treatment of B-cell associated diseases, from biotechnology company Curon Biopharmaceutical.

Daiichi Sankyo and MSD Expand Global Collaboration

Japan's Daiichi Sankyo and US drugmaker MSD have expanded their existing global co-development and co-commercialization agreement for three investigational DXd antibody drug conjugates to include MSD’s MK-6070, a compound MSD obtained through its recent acquisition of Harpoon Therapeutics.

MSD Ireland Opens New Site in Dunboyne, Completes Expansion in Carlow

In Ireland, US drugmaker MSD has opened its new facility in Dunboyne, County Meath, and has expanded its Carlow site. MSD says it has invested more than €1 billion at both sites, creating 670 new jobs and increasing the number of employees in Ireland to 3,100. 100 of the newly created positions remain to be filled.

Bayer in Push to Lift US Profile

Merck Wins Hepatitis C Patent Row with Gilead

Sanofi Pasteur and US Merck to End Vaccines JV